REFRACTORY MANTLE CELL LYMPHOMA
Clinical trials for REFRACTORY MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphomas: drug shrinks tumors after CAR t fails
Disease control CompletedThis study tested a drug called glofitamab in 67 people with lymphoma that did not respond or came back after CAR T-cell therapy. The drug is a special antibody that helps the immune system attack cancer cells. The goal was to see if it could shrink tumors and help patients live …
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis study tested the drug nivolumab in 20 people with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal was to see ho…
Matched conditions: REFRACTORY MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 03:54 UTC